BioCardia, Inc. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
BioCardia, Inc. (BCDA) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $389.00 thousand for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-03-16
- BioCardia, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $91.00K, a 18.02% decline year-over-year.
- BioCardia, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $88.00K, a 12.00% decline year-over-year.
- BioCardia, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $101.00K, a 26.81% decline year-over-year.
- BioCardia, Inc. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-03-31 was $109.00K, a 35.12% decline year-over-year.
- BioCardia, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $389.00K, a 24.76% decline from fiscal 2016.
- BioCardia, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $517.00K, a 39.88% decline from fiscal 2015.
- BioCardia, Inc. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $860.00K.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2017-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $179.00K derived: sum of 2 quarters · filed 2018-03-16 | $280.00K derived: sum of 3 quarters · filed 2018-03-16 | $389.00K 10-K · filed 2018-03-16 |
| 2017-09-30 | $88.00K 10-Q · filed 2017-11-09 | $189.00K derived: sum of 2 quarters · filed 2017-11-09 | $298.00K 10-Q · filed 2017-11-09 | $409.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-06-30 | $101.00K 10-Q · filed 2017-08-14 | $210.00K 10-Q · filed 2017-08-14 | $321.00K derived: sum of 3 quarters · filed 2018-03-16 | $421.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2017-03-31 | $109.00K 10-Q · filed 2017-05-11 | $220.00K derived: sum of 2 quarters · filed 2018-03-16 | $320.00K derived: sum of 3 quarters · filed 2018-03-16 | $458.00K derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $211.00K derived: sum of 2 quarters · filed 2018-03-16 | $349.00K derived: sum of 3 quarters · filed 2018-03-16 | $517.00K 10-K · filed 2018-03-16 |
| 2016-09-30 | $100.00K 10-Q · filed 2017-11-09 | $238.00K derived: sum of 2 quarters · filed 2017-11-09 | $406.00K 10-Q · filed 2017-11-09 | |
| 2016-06-30 | $138.00K 10-Q · filed 2017-08-14 | $306.00K 10-Q · filed 2017-08-14 | ||
| 2016-03-31 | $168.00K 10-Q · filed 2017-05-11 | |||
| 2015-12-31 | $860.00K 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |